We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Israel-based biopharmaceutical company Kamada has applied for a FDA license for the production of its Alpha 1-Proteinase Inhibitor (API) for Phase III clinical trials.
Transition Therapeutics announced that patient enrollment has commenced for its regenerative therapy E1-I.N.T. in an exploratory Phase IIa clinical trial in Type II diabetes patients. E1-I.N.T. is a short course combination therapy aimed at stimulating the regeneration of the body's insulin-producing cells, called islet cells.
Pharmacyclics has initiated an open-label Phase II clinical trial of Xcytrin Injection, the company's lead cancer therapeutic candidate, as a second-line treatment for patients with non-small cell lung cancer.
Medivation announced that patient dosing has begun in its Phase II Alzheimer's disease study with Dimebon. This randomized, double-blinded, placebo-controlled study is being conducted at approximately 12 sites in Russia and will enroll up to 166 patients.
Eli Lilly and Alkermes have presented results from a Phase II clinical study of inhaled insulin in people with Type 1 diabetes, showing that patients using the Lilly/Alkermes inhaled insulin system achieved blood sugar levels similar to patients treated with injected insulin.
Biomira announced that PRA International will assist Biomira and Merck KGaA of Darmstadt, Germany, with the planned Phase III trial of BLP25 Liposome Vaccine for the treatment of non-small cell lung cancer.
DOV Pharmaceutical has announced that bicifadine, its non-narcotic and non-NSAID analgesic, provided statistically and clinically significant analgesic effects at 400 mg administered three times daily relative to a placebo control group.
Amarin has reached an agreement with the FDA under the special protocol assessment (SPA) procedure for the design of two pivotal Phase III clinical trials of Miraxion in Huntington's disease.